Progress with scale-up of HIV viral load monitoring — Seven sub-Saharan African countries, January 2015–June 2016

By Shirley Lecher, Jason Williams, Peter N. Fonjungo, Andrea A. Kim, Dennis Ellenberger, Guoqing Zhang, Christiane Adje Toure, Simon Agolory, Georgette Appiah-Pippim, Suzanne Beard, Marie Yolande Borget; Sergio Carmona, Geoffrey Chipungu, Karidia Diallo, Marie Downer, Dianna Edgil, Holly Haberman, Mackenzie Hurlston, Steven Jadzak; Charles Kiyaga,  William Macleod  Boniface Makumb, Hellen Muttai, Christina Mwangi, Jane W. Mwangi, Michael Mwasekaga, Mary Naluguza, Lucy W. Ng'Ang'A, Shon Nguyen, Souleymane Sawadogo, Katrina Sleeman, Wendy Stevens, Joel Kuritsky, Shannon Hader, John Nkengasong,  |  | 

The World Health Organization (WHO) recommends viral load testing as the preferred method for monitoring the clinical response of patients with human immunodeficiency virus (HIV) infection to antiretroviral therapy (ART). Unlike western countries, which have relied on viral load testing to monitor virologic response to ART, low- and middle income countries have historically relied on CD4 cell counts (which monitor immunologic improvement for patients on ART) because of the higher cost of viral load testing.  A previous evaluation found that countries were at various stages of implementation and that scale-up of viral load testing was feasible.

Publication details

MMWR Morb Mortal Wkly Rep